secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2026-09-11T20:08:25+00:00
Accession:  0001808805-26-000041
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus enters new $125M ATM sales agreement with TD Cowen; terminates prior unused agreement
--------------------------------------------------------------------------------

- Entered ATM sales agreement with TD Cowen to sell up to $125M of common stock, with commission up to 3% of gross proceeds.
- Prior ATM agreement dated Feb 28, 2024 mutually terminated; no shares had been sold under it.
- Sales will occur via Rule 415 at-the-market offering under new S-3 shelf registration statement filed Sept 11, 2026.
- Company not obligated to sell any shares and may suspend sales at any time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880526000041/0001808805-26-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880526000041/naut-20260911.htm
  HTML page:      https://secwatch.observer/filing/0001808805-26-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer